While the here reported real-world evidence supports the high clinical efficacy of ICI in advanced melanoma patients, it also suggests that the combination of PD-1- and CTLA-4- blocking antibodies, are mostly beneficial for patients with metastatic disease affecting more than two organ systems. The gene discussed is CTLA4; the disease is melanoma.